This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
Key Questions Answered in this Report:
- What are the major market drivers, challenges, and opportunities in the U.S. hematologic malignancies testing market?
- What are the key development strategies which are being implemented by the major players in order to sustain in the competitive market?
- Which is the dominant product type developed by the leading and emerging players for the diagnosis of hematologic malignancies?
- What are the key technologies that have been used by leading players in the U.S. market for the development of diagnostic solutions for hematologic malignancies?
- How each segment of the market is expected to grow during the forecast period from 2019 to 2025 based on:
- product type
- disease
- technology
- end-user
- country, i.e., U.S.
- Which companies are anticipated to be highly disruptive in the future and why?
- What are the reimbursement scenario and the regulations for the development of diagnostic solutions for the diagnosis of hematologic malignancies, specifically in the U.S.?
The U.S. hematologic malignancies market analysis projects the market to grow at a significant CAGR of 14.60% during the forecast period, 2019-2025. The U.S. hematologic malignancies market generated $723.9 million revenue in 2018, in terms of value.
The U.S. hematologic malignancies market growth has been primarily attributed to the major drivers in this market, such as rising incidence of hematologic malignancies, favorable reimbursement scenario, and increase in funding in the hematologic malignancies market. However, there are factors hindering the growth of the market, such as lack of training professionals, high pricing pressure, and issue pertaining to the analytic validity of genetic testing.
Expert Quote
“In an era of precision and increasingly personalized therapy, the healthcare industry demands cost-effective options that can robustly identify biomarkers to help select cancer patients most likely to benefit from the emerging class of immuno-oncology drug.”
Scope of the Market Intelligence on the U.S. Hematologic Malignancies Market
The U.S. hematologic malignancies market research provides a holistic view of the market in terms of various factors influencing it, including strategic developments and technological advancements.
The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with industrial and biological research. In addition, the study also includes exhaustive information on unmet needs, perception of new products, competitive landscape, market share of leading manufacturers, the growth potential of each underlying sub-segment, and company, as well as other vital information with respect to the U.S. hematologic malignancies market.
Market Segmentation
- The U.S. hematologic malignancies market (on the basis of product type) is segmented into kits and services.
- The U.S. hematologic malignancies market (on the basis of technology) is segmented into polymerase chain reaction, next-generation sequencing, fluorescence in-situ hybridization, immunohistochemistry, flow-cytometry, and other technologies.
- The U.S. hematologic malignancies market (on the basis of disease) is segmented into leukemia, lymphoma, multiple myeloma, myeloproliferative neoplasms, and myelodysplastic syndromes.
- The U.S. hematologic malignancies market (on the basis of end-user) is segmented into specialty clinics and hospitals, research institutions, reference laboratories, diagnostic laboratories, and other end users.
Key Companies in the U.S. Hematologic Malignancies Market
The key manufacturers that have been contributing significantly to the U.S. hematologic malignancies market include Abbott Laboratories, Illumina, Inc., F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Sysmex Corporation, Cancer Genetics Inc., QIAGEN N.V., ICON plc, Quest Diagnostics Incorporated, Invitae Corporation, Opkp Health, Laboratory Corporation of American Holdings, NeoGenomics Laboratories, Inc., ASURAGEN, INC., ArcherDX, Inc., Adaptive Biotechnologies, ARUP Laboratories, and Invivoscribe, Inc, among others.
Enterprise License customers will receive an Excel spreadsheet containing additional data.
Table of Contents
Executive Summary
1 Product Definition
1.1 Inclusion and Exclusion
2 Market Scope
2.1 Scope of Work
2.2 Key Questions Answered in the Report
3 Research Methodology
3.1 U.S. Hematologic Malignancies Testing Market: Research Methodology
3.2 Data Sources
3.3 Secondary Data Sources
3.4 Market Estimation Model
3.5 Criteria for Company Profiling
4 Epidemiology of Hematological Malignancies in U.S.
5 U.S. Hematologic Malignancies Testing Market: Value and Volume Data 2019 (U.S. State Regions)
5.1 Midwest U.S.
5.2 Mid Atlantic
5.3 The Southwest
5.4 New England
5.5 The West
5.6 The South
6 Market Dynamics
6.1 Market Drivers
6.1.1 Rising Incidence of Hematologic Malignancies
6.1.2 Increasing Adoption of Inorganic Growth Strategies in the Market
6.1.3 Favorable Reimbursement Scenario in the U.S. hematologic Malignancies Testing Market
6.1.4 Increase in Funding in Hematologic Malignancies Testing Market
6.2 Restraints
6.2.1 High Pricing Pressure
6.2.2 Lack of Trained Professionals
6.2.3 Issues Pertaining to the Analytical Validity of Genetic Testing for Cancers
6.3 U.S. Market Opportunities
6.3.1 An Underlying Relaxation in Revised 2018 PAMA Criteria
6.3.2 Informatics and Technological Innovation for Larger Consumer Base
6.3.3 Technological Advancements in the Field of Molecular Diagnostics
7 Competitive Landscape
7.1 Key Strategies and Developments
7.1.1 Synergistic Activities
7.1.2 Approvals
7.1.3 Product Launches and Enhancements
7.1.4 Merger, Acquisitions & Expansions
7.2 Product Scenario
7.3 Funding Scenario
7.4 Market Share Analysis
7.5 Growth Share Analysis (Opportunity Mapping)
7.5.1 By Company
7.5.2 By Product
8 Industry Insights
8.1 Regulatory Framework
8.1.1 Legal Requirements and Framework in the U.S.
8.2 Reimbursement Scenario
8.2.1 Protecting Access to Medicare Act (PAMA) Criteria for Advanced Diagnostic Laboratory Tests (ADLT)
8.3 Physicians’ Perceptions
9 U.S. Hematologic Malignancies Testing Market (by Product) 2018-2025 ($ Million)
9.1 Services
9.2 Kits
9.2.1 NGS-Based Gene Panels
9.2.1.1 Leukemia
9.2.1.2 Lymphoma
9.2.1.3 Multiple Myeloma
9.2.1.4 Myeloproliferative Neoplasms
9.2.1.5 Myelodysplastic Syndromes
9.2.2 NGS-Based Molecular Clonality Testing
9.2.2.1 Leukemia
9.2.2.2 Lymphoma
9.2.2.3 Multiple Myeloma
9.2.2.4 Myeloproliferative Neoplasms
9.2.2.5 Myelodysplastic Syndromes
9.2.3 NGS-Based Translocation Testing
9.2.3.1 Leukemia
9.2.3.2 Lymphoma
9.2.3.3 Multiple Myeloma
9.2.3.4 Myeloproliferative Neoplasms
9.2.3.5 Myelodysplastic Syndromes
9.2.4 NGS-Based Mutation Testing
9.2.4.1 Leukemia
9.2.4.2 Lymphoma
9.2.4.3 Multiple Myeloma
9.2.4.4 Myeloproliferative Neoplasms
9.2.4.5 Myelodysplastic Syndromes
9.2.5 NGS-Based Minimal Residual Disease (MRD) Testing
9.2.5.1 Leukemia
9.2.5.2 Lymphoma
9.2.5.3 Multiple Myeloma
9.2.5.4 Myeloproliferative Neoplasms
9.2.5.5 Myelodysplastic Syndromes
10 U.S. Hematologic Malignancies Testing Market (by End User)
10.1 Specialty Clinics and Hospitals
10.2 Diagnostic Laboratories
10.3 Reference Laboratories
10.4 Research Institutions
11 U.S. Hematologic Malignancies Testing Market (by Disease)
11.1 Leukemia
11.2 Lymphoma
11.3 Multiple Myeloma
11.4 Myeloproliferative Neoplasms
11.5 Myelodysplastic Syndromes
12 U.S. Hematologic Malignancies Testing Market (by Technology)
12.1 Next-generation Sequencing (NGS)
12.2 Polymerase Chain Reaction (PCR)
12.3 Fluorescence In-Situ Hybridization (FISH)
12.4 Immunohistochemistry (IHC)
12.5 Flow Cytometry
12.6 Other Technologies
13 Company Profiles
13.1 Overview
13.2 Abbott Laboratories
13.2.1 Company Overview
13.2.2 Role of Abbott Laboratories in the U.S. Hematologic Malignancies Testing Market
13.2.3 Financials
13.2.4 Key Insights About Financial Health of the Company
13.2.5 SWOT Analysis
13.3 Illumina, Inc.
13.3.1 Company Overview
13.3.2 Role of Illumina, Inc. in the U.S. Hematologic Malignancies Testing Market
13.3.3 Financials
13.3.4 Key Insights About Financial Health of the Company
13.3.5 SWOT Analysis
13.4 F. Hoffmann-La Roche Ltd
13.4.1 Company Overview
13.4.2 Role of F. Hoffmann-La Roche Ltd in the U.S. Hematologic Malignancies Testing Market
13.4.3 Financials
13.4.4 Key Insights About Financial Health of the Company
13.4.5 SWOT Analysis
13.5 Bio-Rad Laboratories, Inc.
13.5.1 Company Overview
13.5.2 Role of Bio-Rad Laboratories, Inc. in the U.S. Hematologic Malignancies Testing Market
13.5.3 Financials
13.5.4 Key Insights About Financial Health of the Company
13.5.5 SWOT Analysis
13.6 Sysmex Corporation
13.6.1 Company Overview
13.6.2 Role of Sysmex Corporation in the U.S. hematologic Malignancies Testing Market
13.6.3 Financials
13.6.4 Key Insights About Financial Health of the Company
13.6.5 SWOT Analysis
13.7 ASURAGEN, INC.
13.7.1 Company Overview
13.7.2 Role of ASURAGEN, INC. in the U.S. Hematologic Malignancies Testing Market
13.7.3 SWOT Analysis
13.8 Cancer Genetics Inc.
13.8.1 Company Overview
13.8.2 Role of Cancer Genetics Inc.in the U.S. Hematologic Malignancies Testing Market
13.8.3 Financials
13.8.4 Key Insights About Financial Health of the Company
13.8.5 SWOT Analysis
13.9 QIAGEN N.V.
13.9.1 Company Overview
13.9.2 Role of QIAGEN N.V. in the U.S. Hematologic Malignancies Testing Market
13.9.3 Financials
13.9.4 Key Insights about Financial Health of the Company
13.9.5 SWOT Analysis
13.10 ArcherDX, Inc.
13.10.1 Company Overview
13.10.2 Role of ArcherDX, Inc. in the U.S. Hematologic Malignancies Testing Market
13.10.3 SWOT Analysis
13.11 Adaptive Biotechnologies
13.11.1 Company Overview
13.11.2 Role of Adaptive Biotechnologies in the U.S. Hematologic Malignancies Testing Market
13.11.3 SWOT Analysis
13.12 ICON plc
13.12.1 Company Overview
13.12.2 Role of ICON plc in the U.S. Hematologic Malignancies Testing Market
13.12.3 Financials
13.12.4 SWOT Analysis
13.13 Quest Diagnostics Incorporated
13.13.1 Company Overview
13.13.2 Role of Quest Diagnostics Limited in the U.S. Hematologic Malignancies Testing Market
13.13.3 Financials
13.13.4 SWOT Analysis
13.14 ARUP Laboratories
13.14.1 Company Overview
13.14.2 Role of ARUP Laboratories in the U.S. Hematologic Malignancies Testing Market
13.14.3 SWOT Analysis
13.15 Invivoscribe, Inc.
13.15.1 Company Overview
13.15.2 Role of Invivoscribe, Inc. in the U.S. Hematologic Malignancies Testing Market
13.15.3 SWOT Analysis
13.16 NeoGenomics Laboratories, Inc.
13.16.1 Company Overview
13.16.2 Role of NeoGenomics Laboratories, Inc. in the U.S. hematologic malignancies testing Market
13.16.3 Financials
13.16.4 Key Insights about Financial Health of the Company
13.16.5 SWOT Analysis
13.17 Invitae Corporation
13.17.1 Company Overview
13.17.2 Role of Invitae Corporation, Inc. in the U.S. hematologic malignancies testing Market
13.17.3 Financials
13.17.4 Key Insights about Financial Health of the Company
13.17.5 SWOT Analysis
13.18 Opko Health
13.18.1 Company Overview
13.18.2 Role of Opko Health, Inc. in the U.S. hematologic malignancies testing Market
13.18.3 Financials
13.18.4 Key Insights about Financial Health of the Company
13.18.5 SWOT Analysis
13.19 Laboratory Corporation of America Holdings
13.19.1 Company Overview
13.19.2 Role of Laboratory Corporation of America Holdings in the U.S. Hematologic Malignancies Market
13.19.3 Financials
13.19.4 SWOT Analysis
List of Tables
Table 7.1: Market Players with Key Product Listing
Table 8.1: Reimbursement Coverage
Table 8.2: Key Coverage Providers for Hematologic Malignancies Testing
Table 9.1: Product Portfolio: NGS-Based Gene Panels
Table 9.2: Product Portfolio: NGS-Based Molecular Clonality Testing
Table 9.3: Product Portfolio: NGS-Based Translocation Testing
Table 9.4: Product Portfolio: NGS-Based Mutation Testing
Table 9.5: Product Portfolio: NGS-Based Minimal Residual Disease
Table 13.1: Quest Diagnostics Incorporated Product Portfolio
Table 13.2: Competitive Portfolio of Opko Health OnkoSight with Other Standard Counterparts in the U.S. Hematologic Malignancies Market
List of Figures
Figure 1: Estimated New Cases of Hematologic Malignancies in 2020
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the U.S. Hematologic Testing Market
Figure 3: Key Strategies Incorporated by Stakeholders of U.S. Hematologic Testing Market to Sustain the Competition (from January 2016 to December 2019)
Figure 4: Dominating Segments of the U.S. Hematologic Malignancies Testing Market, 2019 and 2025
Figure 5: U.S. Hematologic Malignancies Testing (by Product), 2019 and 2025
Figure 6: NGS Based U.S. Hematologic Malignancies Testing (by Product), 2019 and 2025
Figure 7: U.S. Hematologic Malignancies Testing Market (by Technology), 2019 and 2025
Figure 8: U.S. Hematologic Malignancies Testing Market (by End-User, 2019 and 2025)
Figure 2.1: U.S. Hematologic Malignancies Testing Market Segmentation
Figure 3.1: U.S. Hematologic Malignancies Testing Market Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Relative Percent of New Hematological Malignancies Expected to be Reported in the U.S. in 2020
Figure 4.2: Relative Percent of New Cases Lymphomas Expected in U.S. in 2020
Figure 4.3: Relative Percent of New Cases of Leukemias in U.S. in 2020
Figure 4.4: Prevalence of Different Hematological Malignancies across U.S. ( 2013-2017)
Figure 4.5: State Specific Prevalence of Leukemia Across Major U.S. States (2017)
Figure 4.6: State Specific Prevalence of Non-Hodgkin’s Lymphoma Across Major U.S. States (2017)
Figure 5.1: Relative Prevalence of Non-Hodgkin’s Lymphoma & Leukaemia in Midwest U.S. (2017)
Figure 5.2: Midwest U.S. Hematologic Malignancies Testing Volume by State, 2019
Figure 5.3: Midwest U.S. Hematologic Malignancies Testing Market Size by State (U.S. $ Mn) 2019
Figure 5.4: Relative Prevalence of Non-Hodgkin’s Lymphoma & Leukemia in Mid-Atlantic U.S. (2017)
Figure 5.5: Mid-Atlantic Hematology Malignancies Testing Market Volume by State (2019)
Figure 5.6: Mid Atlantic Hematology Malignancies Testing Market Size by State (U.S. $Mn) (2019)
Figure 5.7: Relative Prevalence of Non-Hodgkin’s Lymphoma & Leukemia in Southwest U.S. by State (2017)
Figure 5.8: Southwest U.S. Hematologic Malignancies Testing Volume by State, 2019
Figure 5.9: Southwest U.S. Hematologic Malignancies Testing Market Size by State ($ Mn) 2019
Figure 5.10: Relative Prevalence of Non-Hodgkin’s Lymphoma & Leukemia in New England, by State (2017)
Figure 5.11: New England Hematology Malignancies Testing Volume by State, 2019
Figure 5.12: New England Hematology Malignancies Testing Market Size by State ($Mn) 2019
Figure 5.13: Relative Prevalence of Non-Hodgkin’s Lymphoma & Leukemia in the West U.S. (2017)
Figure 5.14: The West U.S. Hematologic Malignancies Testing Volume by State, 2019
Figure 5.15: West U.S. Hematologic Malignancies Testing Market Size by State (USD Mn) 2019
Figure 5.16: Relative Prevalence of Non-Hodgkin’s Lymphoma & Leukemia in the South U.S. (2017)
Figure 5.17: South U.S. Hematologic Malignancies Testing Volume by State, 2019
Figure 5.18: South U.S. Hematologic Malignancies Testing Market Size by State ($ Mn) 2019
Figure 6.1: Market Dynamics of U.S. Hematologic Malignancies Testing Market
Figure 6.2: Leukemia, U.S. Incident Cases (x1000), (2010-2018)
Figure 7.1: Share of Key Developments and Strategies, January 2016 – September 2019
Figure 7.2: Synergistic Activities Share (by Companies), January 2016 – September 2019
Figure 7.3: Approvals Share (by Companies), January 2016 – September 2019
Figure 7.4: Product Launches and Enhancements Share (by Companies), January 2016 – September 2019
Figure 7.5: Acquisition and Merger Share (by Companies), January 2016 – September 2019
Figure 7.6: Market Share Analysis for the U.S. Hematologic Malignancies Testing Market, 2018
Figure 7.7: Growth Share Matrix for U.S. Hematologic Malignancies Testing Market (by Company), 2018
Figure 7.8: Growth Share Matrix for U.S. Hematologic Malignancies Testing Market (by Product), 2018
Figure 8.1: ADLT Parameters
Figure 9.1: U.S. Hematologic Malignancies Testing Market (by Product), 2019 vs 2025
Figure 9.2: U.S. NGS-Based Hematologic Malignancies Testing Market (by Product), 2019 vs 2025
Figure 9.3: U.S. Hematologic Malignancies Testing Services Market, $Million, 2018-2025
Figure 9.4: U.S. NGS-Based Hematologic Malignancies Testing Services Market, $Million, 2018-2025
Figure 9.5: U.S. Hematologic Malignancies Testing Kits Market, $Million, 2018-2025
Figure 9.6: U.S. NGS Based Hematologic Malignancies Testing Kits Market, $Million, 2018-2025
Figure 9.7: Gene Panels Market, $Million, 2018-2025
Figure 9.8: NGS-Based Gene Panels Leukemia Market, $Million, 2018-2025
Figure 9.9: NGS-Based Gene Panels Lymphoma Testing Market, $Million, 2018-2025
Figure 9.10: NGS-Based Gene Panels Multiple Myeloma Testing Market, $Million, 2018-2025
Figure 9.11: NGS-Based Gene Panels Myeloproliferative Neoplasms Testing Market, $Million, 2018-2025
Figure 9.12: NGS-Based Gene Panels Myelodysplastic Syndromes Testing Market, $Million, 2018-2025
Figure 9.13: NGS-Based Molecular Clonality Testing Market, $Million, 2018-2025
Figure 9.14: NGS-Based Molecular Clonality Leukemia Testing Market, $Million, 2018-2025
Figure 9.15: NGS-Based Molecular Clonality Lymphoma Testing Market, $Million, 2018-2025
Figure 9.16: NGS-Based Molecular Clonality Multiple Myeloma Testing Market, $Million, 2018-2025
Figure 9.17: NGS-Based Molecular Clonality Myeloproliferative Neoplasms Testing Market, $Million, 2018-2025
Figure 9.18: NGS-Based Molecular Clonality Myelodysplastic Syndromes Testing Market, $Million, 2018-2025
Figure 9.19: NGS-Based Translocation Testing Market, $Million, 2018-2025
Figure 9.20: NGS-Based Translocation Leukemia Testing Market, $Million, 2018-2025
Figure 9.21: NGS-Based Translocation Lymphoma Testing Market, $Million, 2018-2025
Figure 9.22: NGS-Based Molecular Clonality Multiple Myeloma Testing Market, $Million, 2018-2025
Figure 9.23: NGS-Based Translocation Myeloproliferative Neoplasms Testing Market, $Million, 2018-2025
Figure 9.24: NGS-Based Translocation Myelodysplastic Syndromes Testing Market, $Million, 2018-2025
Figure 9.25: NGS-Based Mutation Testing Market, $Million, 2018-2025
Figure 9.26: NGS-Based Mutation Leukemia Testing Market, $Million, 2018-2025
Figure 9.27: NGS-Based Mutation Lymphoma Testing Market, $Million, 2018-2025
Figure 9.28: NGS-Based Mutation Multiple Myeloma Testing Market, $Million, 2018-2025
Figure 9.29: NGS-Based Mutation Myeloproliferative Neoplasms Testing Market, $Million, 2018-2025
Figure 9.30: NGS-Based Mutation Myelodysplastic Syndromes Testing Market, $Million, 2018-2025
Figure 9.31: NGS-Based Minimal Residual Disease (MRD) Testing Market, $Million, 2018-2025
Figure 9.32: NGS-Based MRD Leukemia Market, $Million, 2018-2025
Figure 9.33: NGS-Based Translocation Lymphoma Testing Market, $Million, 2018-2025
Figure 9.34: NGS-Based Minimal Residual Disease Multiple Myeloma Testing Market, $Million, 2018-2025
Figure 9.35: NGS-Based Minimal Residual Disease Myeloproliferative Neoplasms Testing Market, $Million, 2018-2025
Figure 9.36: NGS-Based Minimal Residual Disease Myelodysplastic Syndromes Testing Market, $Million, 2018-2025
Figure 10.1: U.S. Hematologic Malignancies Testing Market (by End User), 2019 vs 2025
Figure 10.2: Specialty Clinics and Hospitals Market, $Million, 2018-2025
Figure 10.3: Diagnostic Laboratories Market, $Million, 2018-2025
Figure 10.4: Reference Laboratories Market, $Million, 2018-2025
Figure 10.5: Research Institutions Market, $Million, 2018-2025
Figure 11.1: U.S. Hematologic Malignancies Testing Market (by Disease), 2019 vs 2025
Figure 11.2: U.S. Leukemia Testing Market, $Million, 2018-2025
Figure 11.3: U.S. Lymphoma Testing Market, $Million, 2018-2025
Figure 11.4: U.S. Multiple Myeloma Testing Market, $Million, 2018-2025
Figure 11.5: U.S. Myeloproliferative Neoplasms Testing Market, $Million, 2018-2025
Figure 11.6: U.S. Myelodysplastic Syndromes Testing Market, $Million, 2018-2025
Figure 12.1: U.S. Hematologic Malignancies Testing Market (by Technology), 2019 vs 2025
Figure 12.2: U.S. Hematologic Malignancies Testing Market by NGS, $Million, 2018-2025
Figure 12.3: U.S. Hematologic Malignancies Testing Market by PCR, $Million, 2018-2025
Figure 12.4: U.S. Hematologic Malignancies Testing Market by FISH, $Million, 2018-2025
Figure 12.5: U.S. Hematologic Malignancies Testing Market by Immunohistochemistry, $Million, 2018-2025
Figure 12.6: U.S. Hematologic Malignancies Testing Market by Flow Cytometry, $Million, 2018-2025
Figure 12.7: U.S. Hematologic Malignancies Testing Market by Other Technologies, $Million, 2018-2025
Figure 13.1: Total Number of Companies Profiled
Figure 13.2: Abbott Laboratories: Overall Product Portfolio
Figure 13.3: Abbott Laboratories: Overall Financials, 2016-2018
Figure 13.4: Abbott Laboratories: Revenue (by Segment), 2016-2018
Figure 13.5: Abbott Laboratories: Revenue Split for Diagnostics, 2016-2018
Figure 13.6: Abbott Laboratories: Revenue (by Region), 2016-2018
Figure 13.7: Abbott Laboratories: R&D Expenditure, 2016-2018
Figure 13.8: Abbott Laboratories: SWOT Analysis
Figure 13.9: Illumina, Inc.: Overall Product Portfolio
Figure 13.10: Illumina, Inc.: Overall Financials, 2017-2019
Figure 13.11: Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 13.12: Illumina, Inc.: Revenue (by Region), 2017-2019
Figure 13.13: Illumina, Inc.: R&D Expenditure, 2017-2019
Figure 13.14: Illumina, Inc.: SWOT Analysis
Figure 13.15: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 13.16: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 13.17: F. Hoffmann-La Roche Ltd: Sales (by Segment), 2017-2019
Figure 13.18: F. Hoffmann-La Roche Ltd: Sales (by Region), 2017-2019
Figure 13.19: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 13.20: F. Hoffmann-La Roche: SWOT Analysis
Figure 13.21: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 13.22: Bio-Rad Laboratories, Inc.: Overall Financials, 2016-2018
Figure 13.23: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2016-2018
Figure 13.24: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2016-2018
Figure 13.25: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2016-2018
Figure 13.26: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 13.27: Sysmex Corporation: Overall Product Portfolio
Figure 13.28: Sysmex Corporation: Overall Financials, 2016-2018
Figure 13.29: Sysmex Corporation: Sales (by Segment), 2016-2018
Figure 13.30: Sysmex Corporation: Sales (by Region), 2016-2018
Figure 13.31: Sysmex Corporation: R&D Expenditure, 2016-2018
Figure 13.32: Sysmex Corporation: SWOT Analysis
Figure 13.33: ASURAGEN, INC.: Overall Product Portfolio
Figure 13.34: ASURAGEN, INC.: SWOT Analysis
Figure 13.35: Product Portfolio: Cancer Genetics Inc.
Figure 13.36: Cancer Genetics Inc.: Overall Financials, 2016-2018
Figure 13.37: Cancer Genetics Inc.: Sales (by Segment), 2016-2018
Figure 13.38: Cancer Genetics Inc.: Sales (by Region), 2016-2018
Figure 13.39: Cancer Genetics Inc.: R&D Expenditure, 2016-2018
Figure 13.40: Cancer Genetics Inc.: SWOT Analysis
Figure 13.41: QIAGEN N.V.: Overall Product Portfolio
Figure 13.42: QIAGEN N.V.: Overall Financials, 2016-2018
Figure 13.43: QIAGEN N.V.: Revenue (by Segment), 2016-2018
Figure 13.44: QIAGEN N.V.: Revenue (by Region), 2016-2018
Figure 13.45: QIAGEN N.V.: R&D Expenditure, 2016-2018
Figure 13.46: QIAGEN N.V.: SWOT Analysis
Figure 13.47: ArcherDX, Inc.: Overall Product Portfolio
Figure 13.48: ArcherDX, Inc.: SWOT Analysis
Figure 13.49: Adaptive Biotechnologies: Overall Product Portfolio
Figure 13.50: Adaptive Biotechnologies: SWOT Analysis
Figure 13.51: ICON plc: Overall Product Portfolio
Figure 13.52: ICON plc: Overall Financials, 2016-2018
Figure 13.53: ICON plc: Revenue (by Region), 2016-2018
Figure 13.54: ICON plc: SWOT Analysis
Figure 13.55: Quest Diagnostics Incorporated: Overall Product Portfolio
Figure 13.56: Quest Diagnostics Incorporated: Overall Financials, 2016-2018
Figure 13.57: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2016 - 2018
Figure 13.58: Quest Diagnostics Incorporated: SWOT Analysis
Figure 13.59: ARUP Laboratories: Overall Product Portfolio
Figure 13.60: ARUP Laboratories: SWOT Analysis
Figure 13.61: Invivoscribe, Inc.: Overall Product Portfolio
Figure 13.62: Invivoscribe, Inc.: SWOT Analysis
Figure 13.63: NeoGenomics Laboratories, Inc.: Overall Product Portfolio
Figure 13.64: NeoGenomics Laboratories, Inc.: Overall Financials, 2016-2018
Figure 13.65: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2016-2018
Figure 13.66: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2016-2018
Figure 13.67: NeoGenomics Laboratories, Inc.: SWOT Analysis
Figure 13.68: Invitae Corporation: Overall Product Portfolio
Figure 13.69: Invitae Corporation: Overall Financials, 2016-2018
Figure 13.70: Invitae Corporation: Revenue (by Segment), 2016-2018
Figure 13.71: Invitae Corporation: Revenue (by Geography), 2016-2018
Figure 13.72: Invitae Corporation: R&D Expenditure, 2016-2018
Figure 13.73: Invitae Corporation: SWOT Analysis
Figure 13.74: Opko Health: Overall Services Portfolio
Figure 13.75: Opko Health: Overall Financials, 2016-2018
Figure 13.76: Opko Health: Revenue (by Segment), 2016-2018
Figure 13.77: Opko Health: R&D Expenditure, 2016-2018
Figure 13.78: Opko Health: SWOT Analysis
Figure 13.79: Laboratory Corporation of America Holdings: Overall Services Portfolio
Figure 13.80: Laboratory Corporation of America Holdings: Overall Financials, 2016-2018
Figure 13.81: Laboratory Corporation of America Holdings: Revenue (by Segment), 2016-2018
Figure 13.82: Laboratory Corporation of America Holdings: Revenue (by Region), 2018
Figure 13.83: Laboratory Corporation of America Holdings: SWOT Analysis
Samples
LOADING...
Executive Summary
According to the market intelligence report titled “U.S. Hematologic Malignancies Market - Analysis and Forecast, 2018-2025”, the U.S. hematologic malignancies market was valued at $723.9 million in 2018 and is anticipated to grow over $1,827 million by 2025. The U.S. hematologic malignancies market is expected to grow at a double-digit compound annual growth rate in the forecast period 2019-2029, aided primarily by the impressive growth in the underlying manufacturing market.
Hematologic malignancies refer to blood cancer, affecting the function of blood cells. Generally, bone marrow is the main source of blood cancers, wherein the normal blood cell development process is interrupted by the uncontrolled growth of an abnormal type of blood cell. In the last decade, incident rates for hematologic malignancies, especially leukemia and non-Hodgkin’s lymphoma, in the U.S. have increased considerably. According to the American Cancer Society, leukemia cases have been increasing much faster, from 28,700 cases in 1998 to 60,300 in 2018, an increase of 110%, with an abrupt increase between 2006 and 2007. In addition to this, other hematologic malignancies such as myeloma and lymphomas have also shown a considerable increase in their prevalence in the U.S. There is a lack of accurate information on the total prevalence of clinically significant hematological malignancy subtypes. This is mainly due to the lack of effective diagnostic solutions, as these cancers require a combination of histology, cytology, immunophenotype, cytogenetics, imaging, and clinical data. This rising incidence and lack of comprehensive diagnostic assays have led to the development of next-generation sequencing-based multiplex gene panels for the early diagnosis and monitoring.
According to Nitish Singh, Analyst, “The Service segment is currently the leading contributor in the U.S. hematologic malignancies market and contributed approximately 64.4% to the market value in 2018. This segment is anticipated to grow at a CAGR of 17.20% during the forecast period 2019-2025 and continue dominating the global market in 2025 as well. However, the kits segment is expected to grow at an impressive CAGR of 17.52% during the forecast period 2019-2025. The growth is mainly due to the development of a wide range of assays based on several methods such as gene panels, molecular clonality testing, and translocation testing.”
Research Highlights:
The gene panels segment is the leading contributor in U.S. hematologic malignancies market and contributed approximately 35.7% in the 2018 market value. However, the U.S. hematologic malignancies market for minimal residual disease (MRD) testing is anticipated to witness the fastest growth with CAGR of 18.98% during the forecast period 2019-2025.
F. Hoffmann-La Roche AG is currently the largest shareholder in the U.S. hematologic malignancies market. This market dominance is attributed to the company’s presence within the market through its expansive product portfolio, led by dedicated products.
This market intelligence report provides a multi-dimensional view of the U.S. hematologic malignancies market in terms of market size and growth potential. This research report aims at answering various aspects of the U.S. hematologic malignancies market with the help of key factors driving the market, restraints that can possibly inhibit the overall growth of the market, and the current growth opportunities that are going to shape the future trajectory of the market expansion.
Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the global market and enables the reader to get acquainted with recent market activities, such as product launches and approvals, partnerships, collaborations, business expansions, as well as mergers and acquisitions. The research report provides a comprehensive analysis of the product sales, manufacturers, service providers, and trend analysis by segment, and growth share analysis by geographical region. Additionally, the report provides a comprehensive attractive analysis and opportunity analysis for the entire U.S. hematologic malignancies market for 2019 and 2025.
This report is a meticulous compilation of research on more than 30 players in the market ecosystem and draws upon insights from in-depth interviews with the key opinion leaders of more than 15 leading companies, market participants, and vendors. The report also comprises 18 detailed company profiles including several key players, namely Abbott Laboratories, Illumina, Inc., F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Sysmex Corporation, Cancer Genetics Inc., QIAGEN N.V., ICON plc, Quest Diagnostics Incorporated, Opko Health, Laboratory Corporation of American Holding, Invitae Corporation, NeoGenomics Laboratories, Inc., ASURAGEN, INC., ArcherDX, Inc., Adaptive Biotechnologies, ARUP Laboratories, and Invivoscribe, Inc.
Companies Mentioned
- ARUP Laboratories
- ASURAGEN, INC.
- Abbott Laboratories
- Adaptive Biotechnologies
- ArcherDX, Inc.
- Bio-Rad Laboratories, Inc.
- Cancer Genetics Inc.
- F. Hoffmann-La Roche Ltd
- ICON plc
- Illumina, Inc.
- Invitae Corporation
- Invivoscribe, Inc.
- Laboratory Corporation of America Holdings
- NeoGenomics Laboratories, Inc.
- Opko Health
- QIAGEN N.V.
- Quest Diagnostics Incorporated
- Sysmex Corporation
